HomeMarkets overviewSharesCorvus Pharmaceuticals, Inc.

Trade Corvus Pharmaceuticals, Inc. - CRVS CFD

Market is not available at the momentMarket information is presented
as of 2026-06-23 19:46:10
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread0.078
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.021457 %
(-$1.07)

Trade size with leverage ~ $5,000.00

Money from leverage ~$4,000.00


-0.02146%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.000765 %
(-$0.04)

Trade size with leverage ~ $5,000.00

Money from leverage ~$4,000.00


-0.00076%
Overnight funding adjustment time21:00 (UTC)
CurrencyUSD
Min traded quantity10
Margin20.00%
Stock exchangeUnited States of America
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close12.531
Open12.301
1-Year Change213.13%
Day's Range12.301 - 13.011

Trade Corvus Pharmaceuticals, Inc. - CRVS CFD

About Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which is engaged in the development and commercialization of precisely targeted oncology therapies. The Company develops drugs and antibodies that target the critical cellular elements of the immune system. The Company's lead product candidate is CPI-006, a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its next product candidate, CPI-818, is a selective, covalent inhibitor of ITK. CPI-818 is designed to inhibit the proliferation of certain malignant T-cells. Its third product candidate, Ciforadenant is an oral, small molecule antagonist of the A2A receptor for adenosine. Its product candidate pipeline includes CPI-006, B-Cell Activating anti-CD73 antibody; CPI-818, ITK Inhibitor, Ciforadenant Adenosine A2A Receptor Antagonist; CPI-182, Anti-CXCR2 Antibody designed to block inflammation and Myeloid Suppression; and CPI-935, Adenosine A2B Receptor Antagonist.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Corvus Pharmaceuticals Inc revenues was not reported. Net loss increased from $6M to $43.2M. Higher net loss reflects Gain on deconsolidation of Angel Pharmac decrease from $37.5M (income) to $0K, Loss from equity method investment increase from $234K to $4.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.20 to -$1.03.

Latest shares articles

BPER Banca stock forecast: Sondrio merger integration
BPER Banca is an Italian banking group listed in Milan, with recent results reflecting the completed €5.4bn integration of Banca Popolare di Sondrio. Explore third-party BPE price targets and technical analysis. Past performance is not a reliable indicator of future results.
7 hours ago
Assicurazioni Generali stock forecast: Moody’s upgrade, UniCredit stake
Assicurazioni Generali is an Italian insurer whose 2026 share performance follows a Moody’s rating upgrade and UniCredit’s disclosed 8.72% stake. Explore third-party G price targets and technical analysis. Past performance is not a reliable indicator of future results.
14:39, 16 June 2026
Intesa Sanpaolo stock forecast: MPS offer in focus
Intesa Sanpaolo is an Italian banking group in focus after its €30.60bn MPS offer, launched amid ECB rate moves and wider European bank consolidation. Explore third-party ISP price targets and technical analysis. Past performance is not a reliable indicator of future results.
14:30, 16 June 2026
Leonardo stock forecast: Avincis order, Iveco deal
Leonardo is an Italian aerospace and defence group. In June 2026, it announced an Avincis helicopter order and received EU approval for its Iveco Defence deal. Explore third-party LDO price targets and technical analysis. Past performance is not a reliable indicator of future results.
13:52, 16 June 2026

User feedback and ratings

Read the feedback from our clients1, whatever their experience level.
2025-07-01
P**** R******

I'm learning the basics of stock investing. This platform is clear and pretty good. I've been using it for over 6 months.

2025-07-01
V***** F******* N***** S****

Great customer service I got to say that. They helped get my account back very fast, after i logged myself out by losing my old email, it was so fast you wouldn’t believe it thank you once again.

2025-06-30
B******

Everything worked as expected from the 1 day. I didn’t have to search how to use the platform, it’s intuitive. The support chat was there when I had a tiny issue.

2025-06-27
G** G******

Capital.com has been great for both learning and trading. The app is clean, fast, and packed with useful tools. Customer support has been solid too. Definitely recommended for beginners and active traders alike.

2025-06-24
R**************

I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!

2025-06-22
J*** A.

The app is built to make options and figures easy to understand, great for beginners and intermediate traders. Demo accounts are simple to set up. 100:1 leverage is available.

2025-06-22
D******

Deposits and withdrawals work without issues. Very low spreads. No noticeable fees. Easy to follow.

2025-06-19
d*********

I would like to express a huge thank you to Evgeniya Logvinovich, customer service manager. For your attention and heartfelt attitude to your clients.❤️

2025-06-16
f*********

I am extremely happy with this broker. Great spreads, good selection of instruments, well coded toolbox.

2025-05-29
C*********

Love the TV integration. Makes traders life smooth and comfortable.

2025-05-20
G****

I’d been paper trading for 2yrs now, went live and this platform is easy for beginners to understand and navigate all important tools to execute all that I learned. Earning now!

2025-04-29
d******

This application is perfect.. simple, easy to use, run smoothly and fast and it has an accurate graphics.. be careful to use only one credit card and one bank account to prevent any withdrawal problem.. overnight fees and spread variation will be repaid for you by the next month.. I used many application but this is the best one

2025-02-06
N***** B***

User friendly app & interface and good support team. Funds transfer ease & Leverage is an advantage but crypto is highly risky be responsible of your loss limits and risks appetite.

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Three steps to get started

1. Create your account (subject to eligibility)2. Deposit on your terms3. Trade when you’re ready